A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02508467 |
|
Recruitment Status :
Active, not recruiting
First Posted : July 27, 2015
Last Update Posted : August 15, 2022
|
Sponsor:
Blueprint Medicines Corporation
Information provided by (Responsible Party):
Blueprint Medicines Corporation
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Actual Primary Completion Date : | June 30, 2021 |
| Estimated Study Completion Date : | December 31, 2022 |